Leclercq V, Torck M, Guislain B
Pharmacie centrale, CHRU de Lille.
Ann Pharm Fr. 1996;54(2):85-8.
Some authors have suggested the administration subcutaneous of copper histidinate for the treatment of the Menkes disease. The purpose of this study was to control the complex formation of Cu (II)-L-Histidine in molar ratio 1/2 and to verify the stability in some conditions of determination and validation production.
一些作者建议皮下注射组氨酸铜来治疗门克斯病。本研究的目的是控制摩尔比为1/2的Cu(II)-L-组氨酸的络合物形成,并在某些测定和验证生产条件下验证其稳定性。